Hepta announced a collaboration to map the biology of metabolic dysfunction‑associated steatohepatitis (MASH) using a novel liquid biopsy platform designed to capture multiomic signals from blood. The partnership aims to develop noninvasive diagnostics for earlier MASH detection and to stratify patients for therapeutic trials. The effort combines Hepta’s technology with academic and industry partners to build a molecular atlas of MASH, potentially reducing reliance on liver biopsy. Liquid biopsies analyze circulating biomarkers—DNA, RNA, proteins, and metabolites—and are positioned as a route to scalable screening and longitudinal disease monitoring.